Printer Friendly

QUIDEL SIGNS LICENSE AGREEMENT WITH EPITOPE FOR ORAL SPECIMEN COLLECTION TECHNOLOGY

 SAN DIEGO, May 6 /PRNewswire/ -- QUIDEL Corp. (NASDAQ: QDEL), a leading developer and marketer of rapid diagnostic tests, today announced the signing of a worldwide license and joint collaboration agreement with Epitope Inc. (AMEX: EPT) for the development of a new line of fertility diagnostic tests that utilize oral samples. Under the terms of the agreement, QUIDEL will license the proprietary oral specimen collection technology from Epitope to combine with QUIDEL's recently introduced Generation III one-step test technology. The products developed from this collaboration will complement the company's growing line of Conceive(TM) urine-based one-step tests and provide users with a choice of convenient detection systems.
 The Epitope technology collects an enriched sample from the mouth called mucosal transudate, which is a fluid from the cheek and lower gum tissue. Mucosal transudate samples overcome the limitations encountered with traditional saliva samples which suffer from analyte dilution and "contamination" from enzymes and proteases that are present in the mouth and make testing difficult.
 "Oral sample rapid tests for fertility hormones represent a significant market opportunity for QUIDEL," said Scott L. Glenn, chairman and chief executive officer of QUIDEL Corp. "After looking at numerous saliva technologies, we found Epitope's technology to be superior, and we look to increase QUIDEL's position in the fertility market using this innovative science. The combination of QUIDEL's rapid diagnostic formats and Epitope's oral specimen collection technology should create formidable product opportunity."
 Epitope Inc. is an Oregon corporation utilizing biotechnology to develop and market diagnostic products for AIDS and other indications and, through its agricultural unit, Agritope Inc., superior new plant varieties.
 QUIDEL Corp. develops, manufactures and markets rapid immunodiagnostic products that provide simple, accurate and cost- effective diagnoses in the areas of human fertility, infectious diseases, allergy and autoimmune disorders. These tests are designed for use in the physician's office, clinical laboratory and home testing markets.
 -0- 5/6/93
 /CONTACT: Scott L. Glenn, chairman and CEO, 619-552-7900, or Mark Francois, manager-investor relations, 619-552-7931, both of QUIDEL; or Mary Hagen, investor relations manager of Epitope, 503-641-6115/
 (QDEL EPT)


CO: QUIDEL Corp.; Epitope Inc. ST: California, Oregon IN: MTC SU: LIC

LS-MS -- SD001 -- 5192 05/06/93 08:03 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:May 6, 1993
Words:362
Previous Article:20-YEAR STUDY SHOWS MINORITIES AND WOMEN ON THE RISE IN NATION'S BOARDROOMS; NEARLY HALF THE BOARDS REPORT A MINORITY, 60 PCT HAVE WOMEN
Next Article:ROSS STORES REPORTS FIRST QUARTER SALES
Topics:


Related Articles
EPITOPE REPORTS FIRST-QUARTER RESULTS, RECENT DEVELOPMENTS
MEXICO APPROVES EPITOPE'S ORASURE DEVICE, COMPANY SAYS
EPITOPE RECEIVES ADDITIONAL APPROVAL FOR EXPORT OF ORAL SPECIMEN COLLECTION DEVICE
EPITOPE ANNOUNCES GLOBAL MARKETING/MANUFACTURING PACTS AT SHAREHOLDERS' MEETING
SMITHKLINE BEECHAM'S CONSUMER HEALTH CARE DIVISION REACHES AGREEMENT WITH EPITOPE, INC. TO ENTER THE DIAGNOSTIC MARKET
EPITOPE ANNOUNCES COMPLETION OF DUE DILIGENCE PERIOD FOR AGREEMENT WITH SMITHKLINE BEECHAM
EPITOPE REPORTS FISCAL 1996 FIRST QUARTER RESULTS
EPITOPE REPORTS THIRD QUARTER PROFIT
Epitope Developing Oral Fluid DNA Testing
Epitope Announces FDA Clearance of Oral Fluid Assay For Cannabanoids (Marijuana)

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters